As published in Oncogene, 1 CD151 null mice were backcrossed four generations onto the FVB/N genetic background to increase chemical carcinogenesis sensitivity. 
Although CD151-null mice can have substantial kidney pathology in the FVB/N background, 3, 4 we are confident that kidney pathology is not a major confounding issue in our studies of CD151 in a skin chemical carcinogenesis model, 1 and in an ErbB2 transgene expression model. 5 First, our CD151-null mice showed minimal kidney pathology. During ErbB2 transgene experiments, 5 58 CD151-null mice, backcrossed three generations into FVB/N background, were monitored for nearly 2 years ( Figure 1 ). None of these mice showed signs of edema, progressive kidney failure or enlarged granular kidneys. They were healthy and indistinguishable from CD151 wild-type and heterozygous mice. Representative kidney sections from CD151 wild-type, heterozygous and null mice were hematoxylin and eosin stained. Out of 11 null mice (mean age 444 days), 9 showed minimal-to-mild pathology, 1 showed intermediate pathology and 1 showed more severe pathology. Staining of wild-type and heterozygous mice showed no kidney pathology. Representative images are published as Supplementary Figure W2 in Deng et al. 5 Based on experience with these mice, we did not carry out routine proteinuria analysis. For skin chemical carcinogenesis experiments, 1 20 CD151 null mice were monitored for 28 weeks. Again we observed no edema, progressive kidney failure or enlarged granular kidneys, and except for decreased tumor formation, CD151-null mice were indistinguishable from wild-type and heterozygous mice.
Second, CD151 effects on tumor formation appear to be independent of kidney pathology. Kidney pathology was not observed in CD151 þ / À mice 3 (and also see Supplementary Figure W2 in Deng et al. 5 ). Nonetheless, CD151 þ / À mice show a significant delay in tumor appearance, comparable to the delay seen in CD151 À / À mice (Figure 1 ). CD151 þ / À mice also showed marked reduction in spontaneous metastasis, though not quite to the same extent as CD151 À / À mice (see Figure 2a in Deng et al. 5 ). In the chemical carcinogenesis model, 1 CD151 þ / À mice, compared to wild-type mice, showed significantly reduced tumor multiplicity and significantly diminished progression to squamous cell carcinoma. Clearly, these effects on tumor appearance, metastasis and progression caused by loss of one CD151 allele cannot be attributed to kidney pathology. Reinforcing this point, the mean time until ErbB2-driven tumor appearance for two CD151-null mice with kidney pathology (422 days-samples analyzed in Supplementary Figure W2 , panels D, E; Deng et al.
5
) was nearly identical to the mean time until tumor appearance for eight CD151-null mice with minimal pathology (mean 430 days).
The question remains-why do CD151-null mice used in our tumor experiments 1, 5 appear to have less kidney pathology than other CD151-null mice?
2,3 Our CD151-null mice were generated using 129SvEv ES cells, 6 whereas others were prepared using 129/ OLA 2 and C57BL/6 ES cells. 3 Hence, we speculate that there could be differences in key modifier genes proximal to the CD151 locus. Further experiments will be needed to answer this interesting question. 
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